Evidence map›Paper›PMID 36178556›Full record

ArticleAIDS and behavior2023

Integrating Gender-Based Violence Screening and Support into the Research Clinic Setting: Experiences from an HIV Prevention Open-Label Extension Trial in Sub-Saharan Africa.

Morgan Garcia, Sarah T Roberts, Ashley J Mayo, Rachel Scheckter, Leila E Mansoor, Thesla Palanee-Phillips, Krishnaveni Reddy, Yuthika Naidoo, Carolyne Agwau Akello, Zakir Gaffoor and 10 more

Full text read
In one paragraph

Article in AIDS and behavior, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Morgan GarciaGlobal Health Population and Nutrition, FHI 360, Durham, NC, USA. mgarcia@fhi360.org.ORCID http://orcid.org/0000-0002-7647-6764
Sarah T RobertsWomen's Global Health Imperative (WGHI) RTI International, Berkeley, CA, USA.
Ashley J MayoGlobal Health Population and Nutrition, FHI 360, Durham, NC, USA.
Rachel ScheckterGlobal Health Population and Nutrition, FHI 360, Durham, NC, USA.
Leila E MansoorCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Thesla Palanee-PhillipsFaculty of Health Sciences, Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.
Krishnaveni ReddyFaculty of Health Sciences, Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.
Yuthika NaidooFaculty of Health Sciences, Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.
Carolyne Agwau AkelloMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Zakir GaffoorHIV Prevention Research Unit (HPRU), South African Medical Research Council (SAMRC), Durban, South Africa.
Samantha SivaHIV Prevention Research Unit (HPRU), South African Medical Research Council (SAMRC), Durban, South Africa.
Chenai RushwayaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Kudzai HlahlaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Jane JambayaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Rujeko MakoniUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Evans KachaleCollege of Medicine - Johns Hopkins Bloomberg School of Public Health, Blantyre, Malawi.
Margret NdovieUniversity of North Carolina Project, Lilongwe, Malawi.
Jabulisile ZumaDesmond Tutu HIV Foundation (DTHF) - Emavundleni Clinical Research Site, Cape Town, South Africa.
Elizabeth T MontgomeryWomen's Global Health Imperative (WGHI) RTI International, Berkeley, CA, USA.
MTN-025/HOPE study team

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
The Malawi Clinical Trials UnitUM1AI069518 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACKY M JENNINGS, TAHA E TAHA · 2012 to 2026
$43.8M
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS P30 AI036219NIAID NIH HHS U01 AI069436NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI069518NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

HIV and gender-based violence (GBV) are syndemic in sub-Saharan Africa and provision of support for participants who disclose GBV constitutes part of comprehensive care. Consequently, a process was undertaken to develop, implement, and evaluate standard operating procedures (SOPs) in MTN-025/HOPE, a study of the dapivirine vaginal ring for HIV prevention. The SOP was developed using needs assessment surveys in addition to World Health Organization (WHO) guidelines and other literature. Sites tailored and implemented the SOP through HOPE implementation. At study end, staff reported increased training 32/35 (91.43%); improved confidence (18/26; 69.23%); and improved vicarious trauma prevention onsite (17/28; 60.71%). Leadership reported increased staff competence in GBV response. Obstacles included limited referral organizations and time for follow-up, continued training needs, and cultural norms. Development and implementation of an SOP is a feasible strategy to build a GBV response to improve health systems and support sustained effective use of HIV prevention products.

Indexed as

Acquired Immunodeficiency SyndromeGender-Based ViolenceHIV InfectionsAfrica South of the SaharaFemaleHumansSurveys and QuestionnairesDapivirine vaginal ringGender-based violence responseHIV preventionReferral networksVicarious trauma

Identifiers

PMID36178556
PMCPMC10036410

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read48
identifiers read2
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.